{"entity":{"id":"mangafodipir","kind":"drug","name":"Mangafodipir (withdrawn liver MRI contrast)","aka":["mangafodipir","mangafodipir trisodium","Teslascan"],"tldr":"A liver MRI dye based on manganese that was authorised in Europe from 1997 to 2012 for finding liver metastases and liver cancer, and is no longer available.","summary":"The EMA register lists Teslascan (GE Healthcare AS, EMEA/H/C/000137), authorised on 22 May 1997 as a \"Contrast medium for diagnostic magnetic resonance imaging (MRI) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas\" and an adjunct for focal pancreatic lesions, with the authorisation withdrawn on 21 June 2012. ATC V08CA05. Liver-specific imaging is now done with gadoxetate.","status":"withdrawn","asOf":"2026-11-04","links":[{"label":"EMA: Teslascan","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/teslascan"},{"label":"WHO ATC index V08CA: paramagnetic contrast media","url":"https://atcddd.fhi.no/atc_ddd_index/?code=V08CA&showdescription=no"}],"tags":["contrast-agents-gaps-2026-11","diagnostic"],"related":["gadoxetate-disodium"],"cancers":["hcc","pancreatic"],"sections":[],"technologies":["gadolinium-based-contrast-agents","mri"],"targets":[],"drugs":[],"companies":["ge-healthcare"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo contrast agent gap fill (Drugs@FDA, FDA labels, DailyMed, EMA register, WHO ATC index)","editedOn":"2026-11-04"},"brand":"Teslascan","modality":"Manganese-based contrast agent for MRI of the liver and pancreas (intravenous, withdrawn)","mechanism":"A manganese chelate taken up by liver cells, brightening normal liver on MRI so lesions without normal liver cells stand out.","approvals":[{"region":"EU","year":1997,"indication":"MRI detection of liver lesions suspected to be metastases or hepatocellular carcinoma; adjunct for focal pancreatic lesions","note":"Withdrawn 21 Jun 2012; GE Healthcare AS"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mangafodipir/","neighbours":{"drug":[{"id":"gadoxetate-disodium","kind":"drug","name":"Gadoxetate disodium (liver-specific MRI contrast)","route":"/drugs/gadoxetate-disodium/"}],"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"gadolinium-based-contrast-agents","kind":"technology","name":"Gadolinium-based and other MRI contrast agents","route":"/technologies/gadolinium-based-contrast-agents/"},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/"}],"company":[{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/"}]}}